TY - JOUR
T1 - Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders
AU - Iwayama, Hideyuki
AU - Ishihara, Naoko
AU - Kawahara, Kohei
AU - Madokoro, Yuta
AU - Togawa, Yasuko
AU - Muramatsu, Kanji
AU - Murakami, Ayuka
AU - Kuru, Satoshi
AU - Kumagai, Toshiyuki
AU - Ohashi, Wataru
AU - Nanya, Kengo
AU - Hasegawa, Shinji
AU - Katsuno, Masahisa
AU - Okumura, Akihisa
N1 - Publisher Copyright:
Copyright © 2022 Iwayama, Ishihara, Kawahara, Madokoro, Togawa, Muramatsu, Murakami, Kuru, Kumagai, Ohashi, Nanya, Hasegawa, Katsuno and Okumura.
PY - 2022/9/29
Y1 - 2022/9/29
N2 - Backgrounds: Intramuscular injection of the SARS-CoV-2 vaccine has raised concerns about its use in patients with neuromuscular disorders (NMDs). We evaluated the response of patients with NMDs to the BNT162b2 vaccine. Methods: Healthy subjects, patients with spinal muscular atrophy (SMA), and patients with Duchenne muscular dystrophy (DMD) were included. All participants received two BNT162b2 doses. SARS-CoV-2 antibody titers at baseline and 2 weeks after each vaccination were compared between groups. Residual muscle volume was evaluated in NMDs group. A questionnaire documented adverse reactions. Results: Eleven patients with NMDs (9 with SMA, 2 with DMD; 7 males; aged 32.7 ± 19.3 years) and 346 healthy subjects (60 males, aged 40.0 ± 12.4 years) were included. Antibody titers (U/mL) were similar between groups (baseline: <0.40 vs. <0.40, first vaccination, 145 ± 258 vs. 103 ± 1192, and second vaccination, 1528 ± 1265 vs. 1429 ± 944; p = 1.000, 0.909, and 0.736, respectively). A negative correlation was found between antibody titers and residual muscle volume but was not significant (Mercuri scale, r = −0.429, p = 0.249; fat infiltration rate, r = −0.194, p = 0.618). The adverse reactions were comparable between groups. Conclusion: The BNT162b2 vaccine is safe and effective in patients with NMDs.
AB - Backgrounds: Intramuscular injection of the SARS-CoV-2 vaccine has raised concerns about its use in patients with neuromuscular disorders (NMDs). We evaluated the response of patients with NMDs to the BNT162b2 vaccine. Methods: Healthy subjects, patients with spinal muscular atrophy (SMA), and patients with Duchenne muscular dystrophy (DMD) were included. All participants received two BNT162b2 doses. SARS-CoV-2 antibody titers at baseline and 2 weeks after each vaccination were compared between groups. Residual muscle volume was evaluated in NMDs group. A questionnaire documented adverse reactions. Results: Eleven patients with NMDs (9 with SMA, 2 with DMD; 7 males; aged 32.7 ± 19.3 years) and 346 healthy subjects (60 males, aged 40.0 ± 12.4 years) were included. Antibody titers (U/mL) were similar between groups (baseline: <0.40 vs. <0.40, first vaccination, 145 ± 258 vs. 103 ± 1192, and second vaccination, 1528 ± 1265 vs. 1429 ± 944; p = 1.000, 0.909, and 0.736, respectively). A negative correlation was found between antibody titers and residual muscle volume but was not significant (Mercuri scale, r = −0.429, p = 0.249; fat infiltration rate, r = −0.194, p = 0.618). The adverse reactions were comparable between groups. Conclusion: The BNT162b2 vaccine is safe and effective in patients with NMDs.
UR - http://www.scopus.com/inward/record.url?scp=85139889281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139889281&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.996134
DO - 10.3389/fimmu.2022.996134
M3 - Article
C2 - 36248823
AN - SCOPUS:85139889281
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 996134
ER -
